Otrivine Tegen Neusverstopping (Xylometazoline Hydrochloride)

Xylometazoline is a selective alpha‑adrenergic agonist. By stimulating alpha‑1 and alpha‑2 receptors on the blood vessels of the nasal mucosa, it causes vasoconstriction, which reduces swelling and excess fluid, thereby opening the nasal passages.

The dose of Otrivine Tegen Neusverstopping is determined by the prescribing healthcare professional. Typically, a few sprays per nostril are used, but the exact number and frequency should follow the prescriber’s instructions.

Safety in pregnancy and lactation has not been fully established. Women who are pregnant, planning to become pregnant, or breastfeeding should discuss the use of Otrivine Tegen with their doctor before starting treatment.

To order, visit the product page on gnhindia.com, enter the required quantity, and submit the enquiry form. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Both xylometazoline (Otrivine Tegen) and oxymetazoline belong to the same alpha‑adrenergic decongestant class and provide rapid relief of nasal blockage. Xylometazoline has a slightly longer duration of action, while oxymetazoline may have a marginally faster onset. Choice often depends on physician preference and patient response.

Store the nasal spray at ambient temperature, preferably below 25 °C. Keep it in the original packaging, protect it from moisture and direct sunlight, and ensure the cap is tightly closed when not in use.

The product is administered as a topical intranasal spray. The user tilts the head slightly forward, inserts the nozzle into a nostril, and sprays the prescribed number of actuations while breathing in gently. The same procedure is repeated for the other nostril if required.

Serious risks include rebound congestion (rhinitis medicamentosa) after prolonged use, significant hypertension or tachycardia, severe allergic reactions such as anaphylaxis, and nasal ulceration. Patients should stop use and seek medical advice if any of these symptoms occur.

Individuals who are under 2 years of age, have uncontrolled severe hypertension, are taking monoamine oxidase inhibitors (MAOIs), or have known hypersensitivity to xylometazoline or any excipients in the spray should avoid using Otrivine Tegen.